Risk tables for predicting progression using the 1973 and 2004/2016 WHO grading classification systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A multicenter EAU NMIBC guidelines panel study

Sylvester, Richard; Burger, Max M.; Comperat, E.; Babjuk, M.; Rhijn, Bas van

doi:10.1016/s2666-1683(20)33802-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Grading In Nonmuscle-invasive Bladder Cancer1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several publications debating this issue. The GUPS endorses the system that is promulgated since 1998 and advocated in the WHO 2016 version [21][22][23]. One of the many reasons to develop a twotiered system in 1998 was that in a three-tiered, many cases end up in the middle group (group 2), resulting in a rather heterogeneous group.…”

Section: Grading In Nonmuscle-invasive Bladder Cancermentioning

confidence: 99%

Nonmuscle-invasive bladder cancer, old problems, new insights

Compérat

Wasinger

Oszwald

et al. 2022

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewNonmuscle-invasive bladder cancer (NMIBC) is the most frequent bladder cancer and represents around 75% of bladder cancers. This review will discuss known challenges and recent advances in staging, grading and treatment stratification based on pathology.Recent findingsPathological staging and grading in NMIBC remains challenging and different techniques exist. Substaging has been shown to be of prognostic relevance and to help predict treatment response in patients receiving Bacillus Calmette-Guérin (BCG) therapy, which is the treatment of choice for high-grade NMIBC. Recent advances in molecular classification and artificial intelligence were also able to show promising results in the stratification of patients.SummaryMany challenges in the diagnosis of NMIBC are still unresolved and ask for more prospective research. New technologies, molecular insights and AI will help in the upcoming years to better stratify and manage these patients.

show abstract

Section: Grading In Nonmuscle-invasive Bladder Cancermentioning

confidence: 99%